A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting

Japanese Journal of Clinical Oncology

Volumn 40, Issue 4, 2009, Pages 294-301

  Ho, Ching Liang ^a   Su, Wu Chou ^b   Hsieh, Ruey Kuen ^c   Lin, Zhong Zhe ^d   Chao, Tsu Yi ^a,e  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Chemotherapy; Granisetron; Ramosetron; Vomiting

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; GRANISETRON; ONDANSETRON; OXALIPLATIN; RAMOSETRON; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; HICCUP; HUMAN; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; URIC ACID BLOOD LEVEL; VISUAL ANALOG SCALE; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; MIDDLE AGED; NAUSEA; NEOPLASM; VOMITING;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; DEXAMETHASONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; VOMITING;

EID: 77951216960     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp169     Document Type: Article

References (21)

1. Bliss JM, Robertson B, Selby PJ. The effect of nausea and vomiting upon quality of life measures. Br J Cancer 1992;66:14-23S.
2. Martin M. Myths and realities of antiemetic treatment. Br J Cancer 1992;19:S46-50.
3. Andrews PL, Sanger GJ. Abdominal vagal afferent neurons: an important target for the treatment of gastrointestinal dysfunction. Curr Opin Pharmacol. 2002;2:650-6.
4. Fukui H, Yamamoto M, Sato S. Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol 1992;59:221-6.
5. Leslie RA, Shah Y, Thejomayen M, Murphy KM, Robertson HA. The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol 1990;68:279-88.
6. Endo T, Minami M, Hirafuji M, Ogawa T, Akita K, Nemoto M, et al. Neurochemistry and neuropharmacology of emesis-the role of serotonin. Toxicology 2000;153:189-201.
7. Miner WD, Sanger GJ, Turner DH. Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer 1987;56:159-62.
8. Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al. American Society of Clinical Oncology guideline for antiemetics in Oncology: update 2006. J Clin Oncol 2006;24:2932-47.
9. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med 2008;358:2482-94.
10. Hainsworth J, Harvey W, Pendergrass K, Kasimis B, Oblon D, Monaghan G, et al. A single-blind comparison of intravenous ondansetron, a selective serotonin, with metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 1991;9:721-8.
11. The Italian Group For Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995;6:805-10.
12. . The Italian Group For Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5.
13. del Giglio A, Soares HP, Caparroz C, Castro PC. Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting: results of a meta-analysis of randomized controlled trials. Cancer 2000;89:2301-8.
14. Mystakidou K, Befon S, Liossi C, Vlachos L. Comparison of the efficacy and safety of tropisetron, metoclopramide, and chlorpromazine in the treatment of emesis associated with far advanced cancer. Cancer 1998;83:1214-23.
15. Kamato T, Miyata K, Ito H, Yuki H, Yamano M, Honda K. Anti-emetic effects of YMO6O, a potent and selective serotonin (5HT3)-receptor antagonist in ferrets and dogs. Jpn J Pharmacol 1991;57:387-95.
16. Kamato T, Ito H, Nagakura Y, Nishida A, Yuki H, Yamano M, et al. Mechanisms of cisplatin and m-chlorophenylbiguanide induced emesis in ferrets. Eur J Pharmacol 1993;238:369-76.
17. Kiichiro N, Masanori I, Osamu Y, et al. Clinical evaluation of YMO6O injection in the treatment of nausea and vomiting induced by anticancer drugs. Jpn J Clin Exp Med 1994;71:2765-76.
18. Feng FY, Zhang P, He YJ, Li YH, Zhou MZ, Cheng G, et al. Comparison of the selective serotonin3 antagonists ramosetron and granisetron in treating acute chemotherapy-induced emesis, nausea, and anorexia: a single-blind, randomized, crossover study. Curr Ther Res 2000;61:901-9.
19. Koizumi W, Tanabe S, Nagaba S, Higuchi K, Nakayama N, Saigenji K, et al. A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: is patient preference a better primary endpoint? Chemotherapy 2003;49:316-23.
20. Cheirsiipa A, Sinthusake T, Songsakkaesorn A, Visawaprasit S, Chulaka K, Changkuingdee N. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in cisplatin-based chemotherapy: a randomized controlled trial. Jpn J Clin Oncol 2005;35:695-9.
21. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting: a comparison of their pharmacology and clinical efficacy. Drugs 1998;55:173-89.